AMA enters online forum with Sermo

Share this article:
The American Medical Association (AMA) announced it is partnering with Sermo, the online community for physicians.

The deal is designed to give the 160-year-old group entrée into a fast-growing online forum, which, in turn, wins access to AMA's 130,000-strong membership. Links and references to Sermo, which boasts around 16,000 members, will feature in online and offline AMA publications. Sermo members will gain access to the full text of articles featured in AMA titles, and the site's staff will work with AMA on enhancing the organization's online publications.

“We're becoming a real voice of physicians, but we're not an advocacy organization,” said
Sermo founder Dr. Daniel Palestrant. “There's one organization that does have that mandate to represent the interests of physicians, and that's the AMA.”

In addition to a ready-made online forum and assistance with site design, the AMA will gain free access to the monitoring services that Sermo charges its Wall Street clients for.

Sermo is also in talks with 10-20 pharmaceutical companies about its offering, which would allow companies to see, in anonymized form, what Sermo members are saying about their products.
Launched in September, the fast-growing site offers its physicians-only membership small cash rewards (typically $20) for particularly thoughtful postings, as ranked by their peers.  

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...